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Abstract
Food allergy is increasing in prevalence in westernized countries, leading to significant morbidity
including nutritional deficiencies and growth delay as well as psychosocial burdens and the
potential for fatal anaphylaxis. There is currently no effective form of therapy, and the mainstay of
treatment remains strict avoidance. However, there are a number of promising therapeutic
strategies currently being investigated for the treatment of food allergies. Allergen-specific
approaches, such as various forms of immunotherapy, have been a major focus of investigation
and appear to be promising methods of desensitization. More recently, the addition of anti-IgE
monoclonal antibodies (mAbs) to immunotherapy regimens has been studied. Early work with
antigen-fixed leukocytes in a murine model has shown promise in inducing tolerance, as have
vaccines containing modified recombinant food proteins coadministered with heat-killed
Escherichia coli. Nonspecific approaches include a Chinese herbal formulation, anti-IgE mAbs,
and Trichuris suis ova therapy. The array of treatment modalities currently being investigated
increases the likelihood of finding one or more effective therapies for the treatment of food
allergy.
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Introduction
Food allergy, along with other allergic diseases, has increased in prevalence in westernized
countries over the past decade. A cross-sectional survey of data on food allergy among
children less than 18 years of age revealed an 18 % increase in the prevalence of food
allergy from 1997 to 2007 [1]. In a meta-analysis of 51 studies looking at the rates of allergy
to cow's milk, hen's egg, peanut, fish, and shellfish, self-reported allergy ranged from 3 to 35
%; whereas estimates from six studies using oral food challenges (OFCs) revealed rates of
1–10.8 % [2]. Based on a 2008 Centers for Disease Control and Prevention report, an
estimated 3.9 % of children living in the USA are currently affected by food allergy [3].
Studies in the UK and North America focusing on peanut indicate that prevalence rates have
tripled, going from 0.4 % in 1997 to 1.4 % in 2008 [1, 4, 5]. Children with food allergy were
found to be two to four times more likely to have other atopic diseases such as asthma,
allergic rhinitis, and atopic dermatitis [3].
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Food allergy can be associated with significant morbidity as well as mortality if accidental
ingestion is not adequately treated. In the USA, food allergy is the most common cause of
anaphylaxis evaluated and treated in the emergency department, accounting for 33 % of all
episodes of anaphylaxis in one study [6]. From 2004 to 2006, there was an average of 9,537
hospital discharges per year with a diagnosis related to food allergy among children aged 0–
17 in the USA, representing a greater than 3-fold increase over the past decade. Similar
trends have been reported in the UK [1, 3, 7]. Unfortunately, food-induced anaphylaxis can
be fatal, with more than 90 % of these fatalities caused by reactions to peanuts or tree nuts in
the USA [8]. Nutritional deficiencies and growth delay have been shown in children with
food allergies who are required to be on a restricted diet. In one study, children with two or
more food allergies were found to be shorter, based on height-for-age percentiles, compared
to children with one or no food allergies. A greater number of children with cow's milk
allergy or multiple food allergies were found to consume less than the recommended age-
and gender-specific dietary intake of calcium [9]. A recent study revealed that healthy
infants fed a protein hydrolysate formula had significantly lower weight-for-length z scores
when compared to infants fed with cow's milk formula [10]. These findings could be
extrapolated to children with cow's milk or soy allergies who are required to remain on an
extensively hydrolyzed protein formula. There is also significant psychosocial impact on
patients and families with food allergies. Poorer overall health, more limitations in social
activities, and less vitality were reported among patients with food allergies compared to the
general population. Food-allergic patients reported poorer generic health-related quality of
life than patients with insulin-dependent diabetes mellitus [11, 12]. The rates of reported
bullying among pediatric patients with food allergy is also of concern. In one study, 24 % of
food-allergic respondents reported being bullied, teased, or harassed because of food allergy,
with 86 % of these individuals reporting multiple episodes [13].
Given the fact that there are currently no curative treatments for food allergy or effective
means of preventing disease, the current guidelines for the management of food allergy in
the USA include strict dietary avoidance, nutritional counseling, and emergency treatment in
the setting of accidental ingestions [14, 15]. Fortunately, there are a number of therapeutic
strategies currently being investigated for the treatment and prevention of food allergy [16].
In this review, we will discuss current efforts to treat IgE-mediated food allergy, including
both allergen-specific and nonspecific approaches (Table 1). Allergen-specific approaches
have largely focused on administering gradually increasing doses of antigen via various
routes, either subcutaneous, oral immunotherapy (OIT), sublingual immunotherapy (SLIT),
or epicutaneous immunotherapy (EPIT). Recently, the addition of anti-IgE mAbs to
immunotherapy regimens has also been explored as a potential means for improved safety
and a shortened time to achievement of maintenance dosing. Antigen-coupled splenocytes,
which have been shown to both prevent allergic responses and induce tolerance in a murine
model, offer an alternative allergen-specific approach. Vaccination with modified
recombinant food proteins co-administered with heat-killed Escherichia coli reduced the
severity of anaphylaxis compared to sham-treated mice in an animal model. Nonspecific
approaches include the use of a Chinese herbal formulation, which prevented peanut-
induced anaphylaxis in a murine model. The use of anti-IgE mAbs to reduce the threshold
dose to reactivity to various food allergens is also being investigated. Parasitic helminth
infections have been shown to ameliorate the allergic response in a murine model of peanut
allergy with decreased production of peanut-specific IgE, therefore the use of Trichuris suis
ova in humans with food allergy is also being investigated. These various therapeutic
strategies represent just a portion of the wide array of investigation currently underway into
the treatment of food allergy.
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Pathogenesis: oral tolerance induction
The failure to develop oral tolerance or a loss of oral tolerance has been hypothesized to be
the primary problem in food allergy [17]. The gastrointestinal tract plays a critical role in the
development of oral tolerance, as it is the largest immunologic organ in the body [18]. The
gastrointestinal tract must perform a balancing act, processing ingested food into a form that
can be absorbed and used for energy and growth, while at the same time preventing the entry
of harmful pathogens into the circulation [19]. It accomplishes this through both physiologic
and immunologic mechanisms, and disruption of any of these pathways may lead to
breakdown in oral tolerance induction.
The physiologic barrier is comprised of a single-cell layer of columnar epithelial cells joined
by tight junctions and covered with a mucous layer that collectively works to keep the
internal sterile environment separate from the outside world. Normally, when food is
ingested, luminal and brush border enzymes, bile salts, and gastric acids break down food
proteins, rendering them less immunogenic. These same factors also serve to destroy
pathogens [18]. Alterations in gastric pH with the use of antacids have been shown to
impede gastric protein digestion, thereby inducing a higher risk for food sensitization [20].
In mice, antacid treatment with sucralfate induced changes in the structure of the gut
epithelium and villi, as well as an increase in eosinophils and mucus-producing cells in the
intestine [21]. Additionally, altered intestinal permeability, whether genetically
predetermined or as seen in various disease states as well as during the newborn period, may
promote sensitization via increased exposure to intact proteins [22].
The immunologic component of the gastrointestinal tract consists of innate and adaptive
immune cells, which work together to both promote oral tolerance and provide another layer
of defense against foreign pathogens. The immunologic components of the innate immune
system include polymorphonuclear neutrophils, macrophages, natural killer cells, epithelial
cells, dendritic cells, and Toll-like receptors. Dendritic cells and macrophages in the
intestine appear to play a critical role in both mucosal tolerance as well as initiating robust
immune responses against pathogens. Exactly how this balance is maintained has not been
clearly elucidated, but at least one study found that Wnt-beta-catenin signaling in intestinal
dendritic cells regulates the balance between inflammatory versus regulatory responses in
the gut [23]. The components of the adaptive immune system include intraepithelial and
lamina propria lymphocytes, Peyer patches, and secretory IgA, along with circulating
antibodies such as IgG and IgE that specifically recognize foreign molecules [19].
The development of tolerance ultimately depends on multiple important factors, including
the form and dose of the antigen, underlying host genetics, age, intestinal flora of the host,
as well as other environmental factors. In susceptible hosts, oral tolerance might not develop
after antigen ingestion, or it may be bypassed by presentation of antigen via an alternate
route, such as the respiratory tract or skin [19]. Sensitization can occur via the respiratory
route, as seen in oral allergy syndrome. In this syndrome, sensitization to pollen proteins by
the respiratory route results in IgE that binds certain homologous, typically labile, food
proteins in various fruits and vegetables. Sensitization also appears to be possible after direct
exposure of skin to antigen. This was first shown in a mouse model in which food proteins
were applied to the skin of mice, followed by oral exposure that resulted in systemic allergic
symptoms [24]. Epidemiologic studies from Israel and the UK have suggested that
environmental, rather than, or in the absence of, oral exposure to peanut might promote
sensitization and allergy [25, 26]. More recently, numerous studies have reported that loss-
of-function mutations within the filaggrin (FLG) gene are associated with the development
of atopic dermatitis and other atopic diseases [26]. A recent study evaluated FLG as a
candidate gene in the cause of peanut allergy and found a significant association with peanut
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allergy and loss-of-function mutations in the FLG gene with an odds ratio of 5.3 [27]. The
association of the FLG mutation with peanut allergy was highly significant (P = 0.0008)
even after controlling for coexistent atopic dermatitis. Collectively, these findings may
suggest that early exposure to food protein via the skin, particularly through a disrupted skin
barrier, leads to allergic sensitization and that early oral exposure to food allergen may
induce tolerance.
Allergen-specific therapy
Immunotherapy for food allergy
Allergen immunotherapy refers to the treatment of disease by modulating the immune
response. The ultimate goal of immunotherapy, or any therapy aimed at the treatment of
food allergy, is to achieve tolerance to the inciting food allergen. Tolerance, as it relates to
food allergy, is the state in which a person can consume a food without any allergic
symptoms in weeks, months, or years after cessation of regular exposure to the food antigen
to maintain clinical nonreactivity [14]. This is in contrast to desensitization, which depends
on the regular ingestion or exposure to the food allergen. In this case, when dosing is
interrupted or discontinued, the protective effect may be lost or decreased [16]. The
immunologic mechanisms underlying the development of tolerance are not yet well
understood. It is thought to involve the initial development of regulatory T cells and
deviation away from a TH2 response, followed at some later stage by anergy [28, 29].
Immunologic changes reported after desensitization to food allergens include decreased
reactivity of mast cells and basophils, increased food-specific IgG4 antibodies, and
eventually decreased food-specific IgE antibodies [30–33]. To date, studies using food-
specific immunotherapy have been successful at achieving desensitization; however,
evidence of sustained tolerance has not been shown.
Subcutaneous immunotherapy
The concept of subcutaneous immunotherapy for the treatment of food allergy dates back to
the 1930s when Freeman [34] reported that with the use of immunotherapy consisting of
“rush inoculations,” he induced a state of tolerance in a fish-allergic patient. He found that
this state of desensitization could be maintained if the patient consumed daily cod liver oil.
The use of subcutaneous immunotherapy for the treatment of numerous aeroallergens as
well as stinging-insect allergy has been performed for over a century and is a well-
established practice among allergists [29, 35]. These ideas led one group to study the use of
subcutaneous immunotherapy for the treatment of peanut allergy using aqueous peanut
extract [36]. This double-blind, placebo-controlled trial demonstrated a 67–100 % decrease
in symptoms during a double-blind placebo-controlled food challenge (DBPCFC) in three
subjects who completed the study on peanut immunotherapy. These subjects also had a 2–5-
log reduction in end point skin prick test reactivity to peanut extract. The one placebo-
treated subject who completed the study did not have changes in these parameters [36].
Unfortunately, the study was terminated prematurely after a pharmacy error resulted in a
placebo-treated subject receiving a dose of peanut extract, which tragically ended in death.
This event served to highlight the need for better treatment modalities for peanut allergy but
also demonstrated the serious risks associated with peanut immunotherapy.
A follow-up study was performed in which 12 subjects with peanut allergy were recruited
[37]. Six were treated with injections of peanut extract while six served as untreated control
subjects. In the six treated subjects, a maintenance level of tolerance was first achieved by a
rush protocol and then maintained with weekly injections for at least 1 year. All treated
subjects achieved the maintenance dose of 0.5 ml of 1:100 wt/vol peanut extract; however,
only three subjects remained tolerant of the full dose. At the end of the study, all subjects
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underwent a DBPCFC. The treated group all tolerated an increased peanut threshold dose
and had decreased skin prick test reactivity to peanut extract. Once again, the control group
did not exhibit any of these findings. However, anaphylaxis with respiratory involvement
was induced during 23 % of the doses during the rush phase, with an average of 9.8
epinephrine injections per subject treated with peanut immunotherapy. The safety
parameters did not improve during the maintenance phase, with a rate of systemic reactions
of 39 % and an average of 12.6 epinephrine injections per subject [37]. These studies,
although providing proof of concept that injected food allergen could induce desensitization,
were wrought with significant adverse reactions and therefore discouraged further
investigation of this form of therapy.
Oral immunotherapy
To date, OIT is one of the most actively studied therapeutic approaches for the treatment of
food allergy. OIT involves the regular administration of small amounts of allergen (usually
in a protein powder formulation) orally, mixed in a vehicle such as apple sauce [38]. The
amount of protein powder ingested is gradually increased with dose escalations typically
occurring in a controlled setting, and daily regular ingestion of tolerated doses during the
buildup and maintenance phases occurring at home [16]. The immediate goal of OIT is to
induce desensitization, with the ultimate goal being tolerance. Before and at the end of OIT,
a DBPCFC is often performed to measure the improvement in the amount of allergen
tolerated [39].
The first report of successful OIT was in 1908 and involved a boy with egg-induced
anaphylaxis [40]. There were several additional case reports over the past 100 years;
however, work on OIT did not begin in earnest until 1984, when Patriarca et al. [41] showed
that standardized OIT protocols could successfully treat allergies to cow's milk, egg, fish,
and fruit. The next major advancement in the area of OIT came from a 1999 case report in
which a 12-year-old girl with milk allergy was successfully desensitized using a rush
protocol [42]. In this case, doses were elevated rapidly over a period of days instead of
weeks or months.
One of the earliest and largest studies evaluating the role of OIT in the treatment of food
allergy was published by Patriarca et al. in 2003 [30] and included both children and adults.
This was also the first OIT study to begin evaluating associated immunologic changes.
Fifty-nine patients were enrolled in the study with an additional 16 patients enrolled as
controls. The OIT protocol consisted of administering progressively increasing doses of
food allergen, with dose escalations occurring over a period of 4–6 months. A successful
treatment in 83.3 % of the patients was completed. Several immunologic changes
accompanied successful completion of OIT therapy, namely a decrease in food-specific IgE
levels, an increase in food-specific IgG4 levels, and skin prick test responses, initially
positive and became negative after 18 months. These immunologic changes were similar to
those seen in subcutaneous aeroallergen immunotherapy, suggesting that the defect in oral
tolerance causing food allergy could potentially be overcome with OIT [38].
In 2007, two additional studies were published evaluating the use of OIT to treat cow's milk
and egg allergies in children. Buchanan et al. [43] performed a 24-month pilot study,
enrolling seven children with egg allergy. The OIT protocol consisted of three phases:
modified rush desensitization, buildup, and maintenance. Fifty-seven percent of the subjects
in this study showed evidence of desensitization during the DBPCFC that followed the
study. All subjects tolerated a higher dose of egg during the poststudy DBPCFC compared
to the prestudy food challenge. This study was able to demonstrate desensitization with OIT,
however, did not demonstrate evidence of long-term tolerance, as two subjects reacted to a
second DBPCFC that was administered 3 months after the study. Staden et al. [44]
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performed a study in which 45 children with cow's milk and egg allergies were randomly
assigned to either OIT or an elimination diet. In this study, nine patients (36 %) did not
complete the induction phase secondary to intolerable side effects. After completing OIT,
oral tolerance was assessed with a follow-up oral food challenge after subjects had strictly
avoided either egg or milk for 2 months. Of the 16 patients who completed OIT, nine (36 %
of the original 25 patients) showed tolerance in the follow-up food challenge. However,
seven of the 20 (35 %) control subjects (those who had remained on an elimination diet)
developed spontaneous tolerance, making these results difficult to interpret.
In order to address whether or not OIT could be safely performed in a subgroup of patients
with severe allergic disease, Longo et al. [45] performed a randomized clinical trial with
children older than 5 years of age with severe cow's milk-induced allergic reactions.
Children were randomized to OIT or a strict elimination diet. After 1 year, 11 (36 %) of the
patients treated with OIT tolerated a daily intake of at least 150 mL of cow's milk. Another
16 (54 %) of patients were able to consume between 5 and 150 mL of milk daily. None of
the children in the elimination diet group showed evidence of desensitization on a follow-up
DBPCFC and were unable to tolerate even 5 mL of milk. Not surprisingly, side effects in
this subgroup of patients were common; however, only three of the 30 subjects on OIT were
unable to complete the protocol, demonstrating that OIT could be administered in patients
with severe food allergies.
Skripak et al. [46] performed the first double-blind, placebo-controlled OIT trial. Twenty
children with cow's milk allergy were randomly assigned to OIT or placebo. Children in the
OIT group showed a significant increase in the amount of milk they were able to tolerate
without a reaction (median of 5,140 mg after OIT). This was in contrast to the placebo
group, in which all children reacted at 40 mg. Reported side effects were notably higher in
the treatment group than in the placebo group, with 45 % of daily doses resulting in
symptoms, compared with 11 % in the placebo group.
Despite the fact that about 85 % of children allergic to foods such as cow's milk, egg, wheat,
and soy develop tolerance and “outgrow” their allergy whereas only 15–20 % of children
allergic to peanut, tree nut, and shellfish develop spontaneous tolerance, little research had
focused on the use of OIT in peanut allergic individuals [47, 48]. This changed in 2009, and
there have since been four seminal papers published evaluating the use of OIT in peanut-
allergic patients. Clark et al. [49] described four patients with challenge-documented peanut
allergy who underwent OIT. All four children had significant increases in the amount of
peanut tolerated, each ingesting between 10 and 12 peanuts during the postintervention food
challenge. That same year, Jones et al. [32] reported on a larger, open-label peanut OIT
study. Thirty-nine patients were enrolled with a median age of 57.5 months. Of the 39
patients, 29 (74 %) completed the trial. During the final food challenge, 27 of these patients
were able to safely consume 16 peanuts, and the other two patients were able to consume
nine peanuts. These results were exciting, as they appeared to provide evidence that OIT
could be used to protect peanut-allergic individuals from anaphylaxis after accidental peanut
ingestion.
An important aspect of the Jones' study was the evaluation of several immunologic
parameters [32]. They found that there was a distinct pattern of immunologic changes
leading to a dampened allergic response underlying the clinical benefits of OIT. Some of the
observed changes, namely a decrease in allergen-specific IgE and an increase in allergen-
specific IgG4, were confirmation of previously reported findings. Novel findings included
suppression of mast cells and basophils, an increase in peanut-specific Fox P3+ T regulatory
cells (Tregs) for 12 months, followed by a decrease in these cells, as well as a change in the
secretion of IL-10, IL-5, IFN-γ, and TNF-α [32, 38, 50].
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A subsequent study, published in 2010 by Blumchen et al. [51], attempted to evaluate
whether or not peanut OIT could induce tolerance, as measured after a 2-week period of
complete peanut elimination. Subjects underwent a rush desensitization, buildup dosing, and
then remained on maintenance dosing for 2 months. This was followed by 2 weeks of
avoidance of any peanut-containing products and then a DBPCFC to assess early tolerance.
They found that even after 2 weeks of therapy, all patients (n = 14) showed a median 4-fold
increase in the threshold dose of peanut tolerated when compared to their entry DBPCFC.
The tolerated dose of peanut increased to a median of 1 g of peanut (equivalent to three to
four peanuts) at the final DBPCFC. Three patients did not react at all during the final
challenge, tolerating 4 g of peanut. Regarding the utility of a rush desensitization protocol
for peanut-allergic subjects, the authors concluded that, although safe, it was unlikely to be
useful since only children with low levels of peanut-specific IgE reached a maintenance
protective dose after undergoing OIT by using the rush protocol. Furthermore, many of these
subjects subsequently had their dose decreased because of refusal to take the dose or of
adverse events [51].
Varshney et al. [31] published the first randomized, double-blind, placebo-controlled study
of OIT for peanut allergy in 2011. Twenty-eight subjects were enrolled with 19 of them
randomized to the OIT group and nine randomized to the placebo group. The median age in
this study was 69 months. Of the 19 patients treated with OIT, 16 (84 %) completed the OIT
protocol, reaching the maintenance dose of 4,000 mg by 40 weeks. All subjects in the OIT
group were able to tolerate a cumulative final dose of 5,000 mg of peanut compared to a
median cumulative dose of 280 mg in the placebo group. One of the OIT subjects reacted
with clinically significant symptoms during the final DBPCFC compared to eight of the nine
subjects treated with placebo [31, 50]. Unlike previous studies, peanut-specific IgE
increased initially, but was unchanged at 12 months compared with initial levels. Increased
peanut-specific IgG4 was again observed. The ratio of Tregs increased significantly between
baseline and 12 months.
A meta-analysis published in 2011 sought to determine whether OIT was more effective
than allergen avoidance in the induction of tolerance. It included the previously discussed
studies by Staden et al. [52]. Although all of the included individual studies found tolerance
more likely to occur after OIT compared to avoidance/placebo, analysis of the studies
collectively using χ2 found no significant difference between the treatment and avoidance
groups. The meta-analysis of the included studies found a lower relative risk of allergy after
OIT; however, this did not meet statistical significance. The authors concluded that OIT
could not yet be recommended as a part of routine practice as a means to induce tolerance in
children with IgE-mediated food allergy.
Taken collectively, these studies examining the role of OIT in food-allergic patients
demonstrate the ability of OIT to induce a desensitized state; however, demonstration of
long-term tolerance (i.e., cure) remains elusive. Although many patients can be successfully
desensitized, allergic reactions occurred in most of the subjects in these studies, some of
which were severe [50]. This presents a significant safety concern, especially when
maintenance doses are administered at home without medical supervision. Interestingly, 10–
20 % of patients among the studies fail the initial rush/escalation phase and withdraw from
the protocols secondary to intolerable adverse reactions. The primary reason that most
patients cannot tolerate the daily OIT dosing is significant gastrointestinal symptoms,
including abdominal pain and sometimes vomiting. Another 10–20 % are unable to reach
the full planned maintenance dose [16]. These findings suggest that some patients may be
more difficult than others to desensitize. It is not yet clear what unique qualities this patient
population possesses, but further investigation is ongoing. Before oral immunotherapy can
be used in clinical practice, additional high-quality RCTs are needed to determine optimal
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maintenance doses, ideal duration of therapy, the degree of protection provided, efficacy in
different age groups, cost of therapy, and the need for emergency medications or other
safety precautions during home administration [53].
Sublingual immunotherapy
Sublingual immunotherapy involves the administration of small amounts of allergen, on the
order of micrograms to milligrams, of extract under the tongue with the expectation that it
will be held there for a set amount of time and then swallowed, spit, or dissolved. The mouth
is an optimal site for allergen delivery given the presence of oral Langerhans cells that take
up antigen and have tolerogenic properties. The sublingual mechanism of allergen delivery
has shown clinical efficacy for the treatment of allergic rhinoconjunctivitis caused by
aeroallergens [54].
SLIT with food allergens was first described in a 29-year-old woman with kiwi allergy.
Homogenized and filtered fresh kiwi pulp extract was placed under the tongue three times
daily. After the patient reached maintenance dosing, she was advised to continue to eat daily
kiwi and was able to do so without any adverse symptoms [55]. The first randomized,
double-blind, placebo-controlled trial of SLIT was conducted in adults with hazelnut allergy
confirmed by means of DBPCFC [56]. Of note, 54.5 % of these patients had a history of oral
allergy symptoms, a more limited form of oral pruritus caused by epitopes cross-reactive
with pollens. Treatment extract solution was held under the tongue for at least 3 min and
then spit out. All subjects receiving hazelnut SLIT reached the planned maximum dose with
a 4-day rush protocol, followed by a daily maintenance dose. Systemic reactions were very
rare, occurring in just 0.2 % of the total doses during the rush buildup phase, none of which
required epinephrine. The rate of reactions during the maintenance phase was also very low.
The mean hazelnut quantity provoking objective symptoms increased from 2.29 to 11.56 g
(P = .02, active group) versus 3.49–4.14 g (placebo, not significant). Nearly 50 % of patients
who underwent active treatment reached the highest dose (20 g) compared to only 9 % in the
placebo group. Laboratory data revealed an increase in hazelnut-specific IgG4 and total
serum IL-10 levels after immunotherapy in only the active group [56].
Similar findings were reported in a randomized, double-blind, placebo-controlled trial of
SLIT with Pru p 3, the major peach allergen, in adults with peach allergy [57]. After 6
months of SLIT, the active group tolerated a higher amount of peach (3–9-fold) had a 5.3-
fold decrease in their peach-specific skin prick test, and a significant increase in IgE and
IgG4 to Pru p 3. No significant changes were observed within the placebo group. Adverse
reactions were rare, and most commonly consisted of local reactions restricted to the oral
cavity.
In the first double-blind, placebo-controlled study of peanut SLIT, 18 children (age 1–11
years) were randomized 1:1 to peanut SLIT or placebo and underwent 6 months of buildup
dosing, followed by 6 months of maintenance dosing [33]. The crude peanut extract,
containing the maximum peanut protein concentration of 500 μg/mL, was administered
sublingually, held under the tongue for 2 min, and then swallowed. Subjects receiving
peanut SLIT had a significant increase in the reaction threshold, safely ingesting a median
cumulative dose of 1,710 mg of peanut protein, which is equivalent to six or seven peanuts.
This is in contrast to those receiving placebo, who only safely ingested a median cumulative
dose of 85 mg equivalent to less than one peanut. Subjects receiving SLIT had distinct
immunologic changes as compared to the placebo group. There was a significant decrease in
skin prick test wheal diameter in those in the active treatment group, indicating decreased
mast cell reactivity. Basophil activity was also significantly diminished after 12 months of
peanut SLIT, as evidenced by a lower percentage of CD63+-activated basophils after
stimulation with peanut extract. Peanut-specific IgE levels initially increased over the first 4
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months in the treatment group and then significantly decreased over the remaining 8 months,
a finding not seen in the placebo group. Peanut-specific IgG4 levels significantly increased
in the treatment group compared to the placebo group, in which levels remained unchanged.
After treatment, IL-5 levels were significantly lower in the active treatment group compared
with those in the placebo group. There was an increased percentage of Tregs seen in the
active treatment group when compared to the placebo group; however, the finding was not
statistically significant. This study again had a very favorable safety profile, with only 0.3 %
of active treatment doses requiring treatment with an antihistamine, 0.02 % requiring
treatment with a β-agonist, and no use of epinephrine [33].
In an exploratory study, 30 children with persistent IgE-mediated cow's milk allergy were
randomized to either SLIT or SLIT followed by OIT to assess the safety and efficacy of
these methods in a head-to-head comparison [58]. This group sought to minimize the rate of
adverse reactions by initiating therapy with SLIT and then to determine whether subsequent
treatment with SLIT or OIT might be most promising for use in the treatment of food
allergy. They found that SLIT followed by OIT was much more effective at desensitization
than SLIT alone but was accompanied by a higher risk of systemic side effects. One of ten
subjects treated with SLIT alone was able to consume a full serving of milk without
symptoms after therapy compared to 14 of 20 subjects treated with SLIT followed by OIT.
Multisystem reactions were more than 11 times more likely when OIT was added to the
regimen. These findings can likely be explained in large part by the difference in the dose of
allergen given; the cumulative dose received by subjects in the SLIT group was at least 140-
fold lower than the minimum cumulative OIT dose. The optimal use of SLIT and OIT, either
separately or in combination, remains to be determined.
Epicutaneous immunotherapy
A final approach to delivery of allergen for immunotherapy is through the skin. In this
method, an epicutaneous patch containing soluble allergen is placed on the skin, which leads
to dissemination of the allergen into the stratum corneum. The epicutaneous approach
targets the outermost layer of skin, the epidermis, which has potent immune surveillance via
keratinocytes and Langerhans cells, making it another ideal site for delivery of allergen [59].
In a double-blind placebo-controlled pilot study performed in 18 children (3 months–15
years of age) with physician-confirmed cow's milk allergy and positive OFCs, participants
were assigned to receive therapy with active epicutaneous delivery of either milk powder or
placebo consisting of glucose for 3 months [60]. Treatment consisted of three 48-h
applications of the epicutaneous delivery system per week. At 3 months, the active group
was able to tolerate a cumulative dose of 23.61 mL of milk compared to a cumulative
tolerated dose of 1.77 mL at baseline. The cumulative tolerated dose of cow's milk did not
change in the placebo-treated group. The most common side effects were local pruritus and
eczema at the site of the patch [60].
Peanut EPIT has been studied in several murine models and was shown to be as efficacious
as subcutaneous immunotherapy, based on biologic and physiologic responses in the mice
[61, 62]. A phase I trial is currently underway in the USA to evaluate the safety of peanut
EPIT in peanut-sensitized individuals and a phase II trial is underway in France (http://
ClinicalTrials.gov).
Anti-IgE mAbs (omalizumab) as adjunctive therapy
Humanized monoclonal murine anti-IgE antibodies have been produced that bind to the
constant region of IgE antibody molecules and prevent IgE from binding to high-affinity
FcεRI receptors expressed on the surface of mast cells and basophils as well as low-affinity
FcεRII receptors expressed on B cells, dendritic cells, and intestinal epithelial cells [16].
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Anti-IgE therapy leads to a decrease in free IgE molecules, thereby downregulating the
expression of FcεRI receptors on mast cells and basophils. This results in decreased
activation and release of histamine and other inflammatory mediators [63]. Currently, the
most widely used anti-IgE mAb is omalizumab (Xolair; Genentech, South San Francisco,
CA, USA). It is a recombinant humanized antibody composed of human IgG1 skeleton (95
%) and murine complementarity-determining regions (5 %) [64]. Talizumab (TNX-901;
Tanox, Houston, TX, USA) is a humanized IgG1 mAb administered subcutaneously.
Talizumab's mechanism of action is similar to that of omalizumab with the addition of
inhibiting allergen-specific T-cell activation through interfering with antigen processing and
presentation activities mediated by the FcεRI receptors [65]. Talizumab is currently not
commercially available because of multiple legal battles related to patent infringement.
The use of anti-IgE mAb alone to treat food allergy has been investigated and will be
discussed separately as an example of allergen-nonspecific therapy. However, the concept of
anti-IgE mAb as adjuvant therapy to specific immunotherapy warrants further discussion
here. It was first investigated for the treatment of allergic rhinitis. Several studies showed
that combination therapy significantly reduced symptom burden during the pollen season
[66]. Also of significance, pretreatment with omalizumab showed added safety to the rush
phase of allergen immunotherapy. In one study of ragweed-allergic patients, those treated
with omalizumab and immunotherapy had a 5-fold decrease in the risk of anaphylaxis
caused by rush immunotherapy [67].
Given the preliminary success of food allergen oral immunotherapy and the observations
that anti-IgE mAb can reduce allergic reactions to food allergen challenges, recent studies
have been initiated to examine the role of anti-IgE mAb in combination with oral
immunotherapy [50]. The first study of omalizumab in combination with OIT was a pilot
study, which enrolled 11 subjects (mean age 10.2 years) with IgE-mediated cow's milk
allergy [68]. This study demonstrated that pretreatment with omalizumab was safe and
allowed for a rapid oral desensitization in most of the 11 subjects. Subjects were treated with
omalizumab for 9 weeks and then underwent rush desensitization to milk, increasing the
dose of oral milk from 0.1 to 1,000 mg over a 6-h period. During the ensuing 7–11 weeks,
the dose was escalated to 2,000 mg. Subjects remained on omalizumab throughout the dose
escalation period. Nine of the ten subjects who remained in the study passed a DBPCFC,
with a cumulative dose of 7,250 mg of milk (equivalent to 220 mL of milk) and an
additional open challenge of greater than 4,000 mg of milk without symptoms. The safety
profile was similar to that seen in other milk OIT studies. In an ongoing study using
omalizumab and peanut OIT combination therapy being conducted by Dr. Wesley Burks,
early analysis has revealed a decreased number of side effects during rush desensitization
and dose escalations. Similar to the milk OIT/omalizumab study, achievement of
maintenance dosing of peanut OIT was more rapid compared to OIT alone. Additional OIT
and omalizumab adjunctive therapy studies are underway in New York and in Boston as
well (http://ClinicalTrials.gov). These early studies suggest that omalizumab adjunctive
therapy could improve the rapidity and likelihood of success of oral desensitization in
patients with food allergy, while at the same time improving safety.
Other allergen-specific approaches
Despite the promising preliminary findings in numerous studies examining the role of
immunotherapy in the treatment of food allergy, there remain several significant
weaknesses. One cited weakness is the safety profile of various forms of immunotherapy. As
previously discussed, subcutaneous immunotherapy for food allergy was halted because of
severe side effects [37]. In one of the cited peanut OIT studies, 93 % of subjects experienced
symptoms during the initial escalation day. The estimated risk of symptoms in this study
during dose escalation was 46 and 3.5 % with home dosing [69]. Another limitation to oral
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immunotherapy is the relatively long time period required to reach maintenance dosing and
desensitization, which often takes between 4 months and 1 year [30, 31, 44, 70]. Given these
limitations, several groups have undertaken other allergen-specific approaches for the
treatment of food allergy.
Antigen-coupled splenocytes
One such method under investigation is the injection of antigens attached to the surface of
syngeneic splenic leukocytes (antigen-coupled splenocytes [Ag-SPs]) with the chemical
cross-linking agent 1-ethyl-3-(3′-dimethylaminopropyl)-carbodiimide [71]. The intravenous
administration of such Ag-SPs has previously been shown to safely and efficiently induce
Ag-specific immune tolerance [72]. Ag-SP tolerance has been shown to prevent and treat
preestablished symptoms of Th1/Th17-mediated autoimmune disease, such as type 1
diabetes mellitus, and promote potent alloantigen-specific tolerance for specific long-term
protection of transplanted allogeneic pancreatic islets in the absence of immunosuppressant
drugs [73]. In this most recent series of experiments, authors demonstrate efficacy of
antigen-coupled splenocyte treatment both in the prevention of allergic responses and in
induction of tolerance in a presensitized murine model of peanut allergy. Specifically, in
their whole peanut extract/SEB-induced food allergy model, whole peanut-extract
splenocytes effectively inhibited the anaphylactic symptoms and drops in body temperature
seen after oral whole peanut extract challenge [71]. This data demonstrate that Ag-SP
treatment can induce protective antigen-specific tolerance in models of Th2-mediated
immune responses and may serve as a future therapy in the prevention and treatment of food
allergy.
Modified recombinant food protein vaccines
Another allergen-specific approach being investigated is the administration of a vaccine
containing recombinant modified peanut proteins. This approach has been pursued because
modifying the antigenic epitopes can diminish the risk of immediate allergic reactions
during immunotherapy. This is accomplished with point mutations introduced by site-
directed mutagenesis or with protein polymerization [74, 75]. Modified food allergens can
be combined with bacterial adjuvants such as heat-killed Listeria monocytogenes or
nonpathogenic E. coli. This serves to enhance the TH1 skewing effect, thereby decreasing
the TH2 skewing effect. In a mouse model, rectal administration of a vaccine containing
heat-killed E. coli expressing the modified peanut proteins Ara h 1–3, led to reduced
severity of anaphylaxis when compared to a sham-treated group [74]. This finding led to the
development of EMP-123, a vaccine containing three recombinant modified peanut proteins
(Ara h 1–3) encapsulated within heat or phenol-killed E. coli developed for rectal




Traditional Chinese medicine (TCM) has a long and rich history of use in treating human
disease in China and other Asian countries and is gaining more widespread acceptance in
Western countries as well. Numerous publications have shown that TCM shows promise in
the treatment of allergic asthma [76–80]. More recently, a specific Chinese herbal
formulation, Food Allergy Herbal Formula-2 (FAHF-2), has been investigated for the
treatment of food allergy. FAHF-2 is derived from Wu Mei Wan, which has been used to
treat parasitic infections and food allergy-like symptoms and is an extract of nine herbs [81].
Studies have shown that FAHF-2 protects against peanut-induced anaphylaxis in a murine
model and that this protection persists for at least 6 months after a single 7-week course of
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therapy, suggesting the development of tolerance [82–84]. FAHF-2 appears to have
immunologic effects on T and B lymphocytes, as well as effector cells such as mast cells
and basophils [85]. A reduction in TH2 cytokine and serum IgE levels as well as increased
levels of IFN-γ and IgG2a were observed in these murine studies. Basophil and mast cell
numbers as well as mast cell activation was also reduced [84, 86].
The early animal studies using FAHF-2 demonstrated efficacy as well as safety, as mice fed
24 times the effective dose of FAHF-2 showed no morbidity or mortality [83]. Given these
promising findings, a randomized, double-blind, placebo-controlled, dose-escalation phase I
trial in subjects with peanut, tree nut, or both; fish; and shellfish allergies followed. In this 1-
week study, FAHF-2 was found to be safe and well tolerated [87]. To further ensure the
safety and tolerability of this formulation before phase II study, an open-label, single-dose,
6-month extension of the phase I study was conducted. The results of this study were
consistent with the acute phase I study, namely FAHF-2 was found to be safe and well
tolerated by patients with food allergy. They also found that FAHF-2 reduced allergen-
stimulated basophil activation, hyperreleaseability, and percentages of circulating basophils.
The suppression of basophil activation and FAHF-2's in vitro effects on PBMCs (increased
IL-10 and IFN-γ and reduced IL-5 levels in mice with peanut allergy) suggests that FAHF-2
leads to beneficial immunologic effects [83–85, 87]. A phase II extended safety and efficacy
trial is currently enrolling subjects with peanut, tree nut, sesame, fish, or shellfish allergy
(http://ClinicalTrials.gov).
Anti-IgE monoclonal antibodies
There have been a limited number of studies evaluating the efficacy of anti-IgE mAb in the
treatment of food allergy. In the largest randomized, double-blind, placebo-controlled study
conducted in 2003, 84 patients (aged 12–60 years) with a history of peanut allergy were
enrolled [65]. Prior to enrollment, a DBPCFC was performed to confirm peanut reactivity.
Patients were randomly assigned to receive talizumab, the anti-IgE mAb used in this study,
at varying doses or placebo every 4 weeks. The mean amount of peanut flour that elicited
symptoms during a food challenge, i.e., the sensitivity threshold, increased in all groups but
was statistically significant only in the group receiving the highest dose of talizumab. The
study drug was well tolerated. This study demonstrated the ability of an anti-IgE mAb to
offer some level of protection against unintended ingestion of peanuts.
A phase II, randomized, double-blind, parallel-group, placebo-controlled trial of
omalizumab followed this initial study to further assess the ability of an anti-IgE mAb to
prevent severe allergic reactions in the setting of an accidental ingestion of peanut [88].
Subjects aged 6 years and older were randomized 2:1 to omalizumab or placebo. An entry
DBPCFC was performed to confirm peanut reactivity. Unfortunately, the study was
terminated early secondary to two severe allergic reactions that occurred during the initial
screening peanut challenge. At the time of termination, 26 subjects had completed 24 weeks
of therapy followed by a second DBPCFC. Omalizumab seemed to increase tolerance to
peanut ingestion in the treated subjects: 44.4 % of omalizumab-treated subjects versus 20 %
of placebo subjects could tolerate a peanut challenge of greater than 1,000 mg [88]. Further
study of the use of anti-IgE monoclonal antibody for the treatment of food allergy is
warranted and is being planned.
T. suis ova therapy
T. suis, a parasitic helminth, is currently being studied for its role in modifying the allergic
response. This is based on observational studies that revealed that parasitic helminth
infections could protect against allergic airway inflammation, leading to a milder course of
asthma [89]. In a murine model of peanut allergy, helminth infection led to greatly
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diminished anaphylactic symptoms as well as a decrease in the production of peanut-specific
IgE. This downregulation of peanut-specific IgE was associated with a decrease in the
secretion of IL-13 by peanut-specific T cells [90]. A phase I study is currently recruiting
patients with peanut and tree nut allergy to be given between 100 and 2,500 T. suis ova
every other week for 3 months. This initial study will assess the safety of this therapy
(https://ClinicalTrials.gov).
Conclusions
Food allergy, along with other allergic diseases, has increased in prevalence in westernized
countries and has led to significant morbidity. There is currently no cure for those
individuals suffering with one or more food allergies. Considerable effort has gone into the
development of strategies aimed at curing food allergy over the past 15–20 years. These
studies have not only advanced our understanding of the clinical phenotype and natural
history of food allergy but have also provided valuable insight into the underlying
immunologic mechanisms involved in the development of food allergy as well as the
development of tolerance. While the therapies discussed in this paper remain investigational
at this time, there is hope that one or more therapies will become clinically available in the
near future.
References
1. Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics. 2009;
124(6):1549–1555. [PubMed: 19917585]
2. Rona RJ, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol. 2007;
120(3):638–646. [PubMed: 17628647]
3. Branum AM, Lukacs SL. Food allergy among U.S. children: trends in prevalence and
hospitalizations. NCHS Data Brief. 2008; (10):1–8. [PubMed: 19389315]
4. Sicherer SH, et al. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year
follow-up. J Allergy Clin Immunol. 2010; 125(6):1322–1326. [PubMed: 20462634]
5. Sicherer SH, Sampson HA. Peanut allergy: emerging concepts and approaches for an apparent
epidemic. J Allergy Clin Immunol. 2007; 120(3):491–503. quiz 504–5. [PubMed: 17689596]
6. Decker WW, et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report
from the Rochester Epidemiology Project. J Allergy Clin Immunol. 2008; 122(6):1161–1165.
[PubMed: 18992928]
7. Gupta R, et al. Time trends in allergic disorders in the UK. Thorax. 2007; 62(1):91–96. [PubMed:
16950836]
8. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to
food, 2001–2006. J Allergy Clin Immunol. 2007; 119(4):1016–1018. [PubMed: 17306354]
9. Christie L, et al. Food allergies in children affect nutrient intake and growth. J Am Diet Assoc.
2002; 102(11):1648–1651. [PubMed: 12449289]
10. Mennella JA, Ventura AK, Beauchamp GK. Differential growth patterns among healthy infants fed
protein hydrolysate or cow-milk formulas. Pediatrics. 2011; 127(1):110–118. [PubMed:
21187303]
11. Lieberman JA, Sicherer SH. Quality of life in food allergy. Curr Opin Allergy Clin Immunol.
2011; 11(3):236–242. [PubMed: 21464708]
12. Flokstra-de Blok BM, et al. Health-related quality of life of food allergic patients measured with
generic and disease-specific questionnaires. Allergy. 2010; 65(8):1031–1038. [PubMed:
20121759]
13. Lieberman JA, et al. Bullying among pediatric patients with food allergy. Ann Allergy Asthma
Immunol. 2010; 105(4):282–286. [PubMed: 20934627]
Henson and Burks Page 13













14. Boyce JA, et al. Guidelines for the diagnosis and management of food allergy in the United States:
report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010; 126(6 Suppl):S1–S58.
[PubMed: 21134576]
15. Burks AW, et al. NIAID-sponsored 2010 guidelines for managing food allergy: applications in the
pediatric population. Pediatrics. 2011; 128(5):955–965. [PubMed: 21987705]
16. Nowak-Wegrzyn A, Sampson HA. Future therapies for food allergies. J Allergy Clin Immunol.
2011; 127(3):558–573. quiz 574-5. [PubMed: 21277625]
17. Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: implications
for future treatment. J Allergy Clin Immunol. 2008; 121(6):1344–1350. [PubMed: 18410959]
18. Chehade M, Mayer L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin
Immunol. 2005; 115(1):3–12. quiz 13. [PubMed: 15637539]
19. Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010; 125(2 Suppl 2):S116–
S125. [PubMed: 20042231]
20. Untersmayr E, Jensen-Jarolim E. The role of protein digestibility and antacids on food allergy
outcomes. J Allergy Clin Immunol. 2008; 121(6):1301–1308. quiz 1309-10. [PubMed: 18539189]
21. Pali-Scholl I, et al. Anti-acids lead to immunological and morphological changes in the intestine of
BALB/c mice similar to human food allergy. Exp Toxicol Pathol. 2008; 60(4–5):337–345.
[PubMed: 18524557]
22. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease
pathogenesis. J Allergy Clin Immunol. 2009; 124(1):3–20. quiz 21-2. [PubMed: 19560575]
23. Manicassamy S, et al. Activation of beta-catenin in dendritic cells regulates immunity versus
tolerance in the intestine. Science. 2010; 329(5993):849–853. [PubMed: 20705860]
24. Navuluri L, et al. Allergic and anaphylactic response to sesame seeds in mice: identification of Ses
i 3 and basic subunit of 11s globulins as allergens. Int Arch Allergy Immunol. 2006; 140(3):270–
276. [PubMed: 16699288]
25. Fox AT, et al. Household peanut consumption as a risk factor for the development of peanut
allergy. J Allergy Clin Immunol. 2009; 123(2):417–423. [PubMed: 19203660]
26. Lack G. Update on risk factors for food allergy. J Allergy Clin Immunol. 2012
27. Brown SJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for
peanut allergy. J Allergy Clin Immunol. 2011; 127(3):661–667. [PubMed: 21377035]
28. Vickery BP, et al. Mechanisms of immune tolerance relevant to food allergy. J Allergy Clin
Immunol. 2011; 127(3):576–584. quiz 585-6. [PubMed: 21277624]
29. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen
immunotherapy. Curr Opin Allergy Clin Immunol. 2011; 11(6):586–593. [PubMed: 21986550]
30. Patriarca G, et al. Oral desensitizing treatment in food allergy: clinical and immunological results.
Aliment Pharmacol Ther. 2003; 17(3):459–465. [PubMed: 12562461]
31. Varshney P, et al. A randomized controlled study of peanut oral immunotherapy: clinical
desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011; 127(3):
654–660. [PubMed: 21377034]
32. Jones SM, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J
Allergy Clin Immunol. 2009; 124(2):292–300. 300 e1–97. [PubMed: 19577283]
33. Kim EH, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence
of desensitization. J Allergy Clin Immunol. 2011; 127(3):640–646. e1. [PubMed: 21281959]
34. Freeman J. “Rush” inoculation. Lancet. 1930; 1:744.
35. Hunt KJ, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978;
299(4):157–161. [PubMed: 78446]
36. Oppenheimer JJ, et al. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin
Immunol. 1992; 90(2):256–262. [PubMed: 1500630]
37. Nelson HS, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with
injections of aqueous peanut extract. J Allergy Clin Immunol. 1997; 99(6 Pt 1):744–751.
[PubMed: 9215240]
38. Land MH, Kim EH, Burks AW. Oral desensitization for food hypersensitivity. Immunol Allergy
Clin North Am. 2011; 31(2):367–376. xi. [PubMed: 21530825]
Henson and Burks Page 14













39. Scurlock AM, et al. Pediatric food allergy and mucosal tolerance. Mucosal Immunol. 2010; 3(4):
345–354. [PubMed: 20505663]
40. Schofield AT. A case of egg poisoning. Lancet. 1908; 1:716.
41. Patriarca C, et al. Oral specific hyposensitization in the management of patients allergic to food.
Allergol Immunopathol (Madr). 1984; 12(4):275–281. [PubMed: 6507224]
42. Bauer A, et al. Oral rush desensitization to milk. Allergy. 1999; 54(8):894–895. [PubMed:
10485398]
43. Buchanan AD, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J
Allergy Clin Immunol. 2007; 119(1):199–205. [PubMed: 17208602]
44. Staden U, et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical
patterns of reaction. Allergy. 2007; 62(11):1261–1269. [PubMed: 17919140]
45. Longo G, et al. Specific oral tolerance induction in children with very severe cow's milk-induced
reactions. J Allergy Clin Immunol. 2008; 121(2):343–347. [PubMed: 18158176]
46. Skripak JM, et al. A randomized, double-blind, placebo-controlled study of milk oral
immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008; 122(6):1154–1160.
[PubMed: 18951617]
47. Wood RA. The natural history of food allergy. Pediatrics. 2003; 111(6 Pt 3):1631–1637. [PubMed:
12777603]
48. Fleischer DM. The natural history of peanut and tree nut allergy. Curr Allergy Asthma Rep. 2007;
7(3):175–181. [PubMed: 17448327]
49. Clark AT, et al. Successful oral tolerance induction in severe peanut allergy. Allergy. 2009; 64(8):
1218–1220. [PubMed: 19226304]
50. Nadeau KC, et al. Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food
allergy. Immunol Allergy Clin North Am. 2012; 32(1):111–133. [PubMed: 22244236]
51. Blumchen K, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin
Immunol. 2010; 126(1):83–91. e1. [PubMed: 20542324]
52. Fisher HR, Toit Gd, Lack G. Specific oral tolerance induction in food allergic children: is oral
desensitisation more effective than allergen avoidance? Archives of Disease in Childhood. 2011;
96(3):259–264. [PubMed: 20522461]
53. Thyagarajan A, et al. Peanut oral immunotherapy is not ready for clinical use. J Allergy Clin
Immunol. 2010; 126(1):31–32. [PubMed: 20620564]
54. Durham SR, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease
modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol.
2012; 129(3):717–725. e5. [PubMed: 22285278]
55. Mempel M, et al. Severe anaphylaxis to kiwi fruit: immunologic changes related to successful
sublingual allergen immunotherapy. J Allergy Clin Immunol. 2003; 111(6):1406–1409. [PubMed:
12789247]
56. Enrique E, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind,
placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;
116(5):1073–1079. [PubMed: 16275379]
57. Fernandez-Rivas M, et al. Randomized double-blind, placebo-controlled trial of sublingual
immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009; 64(6):876–883. [PubMed:
19183164]
58. Keet CA, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy.
Journal of Allergy and Clinical Immunology. 2012; 129(2):448–455. e5. [PubMed: 22130425]
59. Otsu K, Fleischer DM. Therapeutics in food allergy: the current state of the art. Curr Allergy
Asthma Rep. 2012; 12(1):48–54. [PubMed: 22101989]
60. Dupont C, et al. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety,
acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010; 125(5):1165–1167.
[PubMed: 20451043]
61. Mondoulet L, et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a
murine model of allergy. Clin Exp Allergy. 2010; 40(4):659–667. [PubMed: 20002446]
Henson and Burks Page 15













62. Mondoulet L, et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in
mice sensitized to peanuts. Int Arch Allergy Immunol. 2011; 154(4):299–309. [PubMed:
20962535]
63. MacGlashan DW Jr, et al. Down-regulation of Fc(epsilon)RI expression on human basophils
during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158(3):1438–
1445. [PubMed: 9013989]
64. Pelaia G, et al. Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther
Adv Respir Dis. 2008; 2(6):409–421. [PubMed: 19124386]
65. Leung DY, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;
348(11):986–993. [PubMed: 12637608]
66. Kuehr J, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in
polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol.
2002; 109(2):274–280. [PubMed: 11842297]
67. Casale TB, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for
ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006; 117(1):134–140.
[PubMed: 16387596]
68. Nadeau KC, et al. Rapid oral desensitization in combination with omalizumab therapy in patients
with cow's milk allergy. J Allergy Clin Immunol. 2011; 127(6):1622–1624. [PubMed: 21546071]
69. Hofmann AM, et al. Safety of a peanut oral immunotherapy protocol in children with peanut
allergy. J Allergy Clin Immunol. 2009; 124(2):286–291. 291 e1-6. [PubMed: 19477496]
70. Meglio P, et al. A protocol for oral desensitization in children with IgE-mediated cow's milk
allergy. Allergy. 2004; 59(9):980–987. [PubMed: 15291907]
71. Smarr CB, et al. Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy. J
Immunol. 2011; 187(10):5090–5098. [PubMed: 21976774]
72. Miller SD, Wetzig RP, Claman HN. The induction of cell-mediated immunity and tolerance with
protein antigens coupled to syngeneic lymphoid cells. J Exp Med. 1979; 149(3):758–773.
[PubMed: 85683]
73. Luo X, et al. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term
survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci U S A. 2008;
105(38):14527–14532. [PubMed: 18796615]
74. Li XM, et al. Persistent protective effect of heat-killed Escherichia coli producing “engineered”,
recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol. 2003;
112(1):159–167. [PubMed: 12847493]
75. Li XM, et al. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes
coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol.
2003; 170(6):3289–3295. [PubMed: 12626588]
76. Chan CK, et al. Ding Chuan Tang, a Chinese herb decoction, could improve airway hyper-
responsiveness in stabilized asthmatic children: a randomized, double-blind clinical trial. Pediatr
Allergy Immunol. 2006; 17(5):316–322. [PubMed: 16846448]
77. Chang TT, Huang CC, Hsu CH. Clinical evaluation of the Chinese herbal medicine formula STA-1
in the treatment of allergic asthma. Phytother Res. 2006; 20(5):342–347. [PubMed: 16619360]
78. Hsu CH, Lu CM, Chang TT. Efficacy and safety of modified Mai-Men-Dong-Tang for treatment
of allergic asthma. Pediatr Allergy Immunol. 2005; 16(1):76–81. [PubMed: 15693916]
79. Kao ST, et al. The effect of Chinese herbal medicine, xiao-qing-long tang (XQLT), on allergen-
induced bronchial inflammation in mite-sensitized mice. Allergy. 2000; 55(12):1127–1133.
[PubMed: 11117269]
80. Li XM, Brown L. Efficacy and mechanisms of action of traditional Chinese medicines for treating
asthma and allergy. J Allergy Clin Immunol. 2009; 123(2):297–306. quiz 307-8. [PubMed:
19203653]
81. Bensky, D.; BR. Chinese herbal medicine: formulas & strategies. Eastland: Seattle; 1990.
82. Qu C, et al. Induction of tolerance after establishment of peanut allergy by the food allergy herbal
formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy. 2007; 37(6):
846–855. [PubMed: 17517098]
Henson and Burks Page 16













83. Srivastava KD, et al. The Chinese herbal medicine formula FAHF-2 completely blocks
anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol. 2005; 115(1):
171–178. [PubMed: 15637565]
84. Srivastava KD, et al. Food Allergy Herbal Formula-2 silences peanut-induced anaphylaxis for a
prolonged posttreatment period via IFN-gamma-producing CD8+ T cells. J Allergy Clin Immunol.
2009; 123(2):443–451. [PubMed: 19203662]
85. Patil SP, et al. Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on
basophils from patients with food allergy: extended phase I study. J Allergy Clin Immunol. 2011;
128(6):1259–1265. e2. [PubMed: 21794906]
86. Song Y, et al. Food allergy herbal formula 2 protection against peanut anaphylactic reaction is via
inhibition of mast cells and basophils. J Allergy Clin Immunol. 2010; 126(6):1208–1217. e3.
[PubMed: 21134573]
87. Wang J, et al. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food
allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1
study. Ann Allergy Asthma Immunol. 2010; 105(1):75–84. [PubMed: 20642207]
88. Sampson HA, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral
food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;
127(5):1309–1310. e1. [PubMed: 21397314]
89. Medeiros M Jr, et al. Schistosoma mansoni infection is associated with a reduced course of asthma.
J Allergy Clin Immunol. 2003; 111(5):947–951. [PubMed: 12743556]
90. Bashir ME, et al. An enteric helminth infection protects against an allergic response to dietary
antigen. J Immunol. 2002; 169(6):3284–3292. [PubMed: 12218148]
Henson and Burks Page 17

























Henson and Burks Page 18
Table 1
Allergen-specific and nonspecific therapies for the treatment of food allergy
Allergen-specific therapies Allergen-nonspecific therapies
Clinical trials Clinical trials
  Immunotherapya   Chinese herbal formulation FAHF-2a
    Subcutaneousa
    Orala   Anti-IgE mAba
    Sublinguala
    Epicutaneousa
    Anti-Ige mAb adjuvant therapya   Probiotics
  Extensively heated milk or egg diet   Anti-IL-5 mAb
  Modified recombinant food protein vaccinesa   Trichuris suis ovaa
Preclinical studies Preclinical studies
  Antigen-coupled splenocytesa   TLR-9 agonist
  Peptide immunotherapy   Lactococcus lactis expressing IL-10 or IL-12
  Plasmid DNA immunotherapy
a
Therapies discussed in this review paper
Semin Immunopathol. Author manuscript; available in PMC 2013 September 01.
